GLP-1 based weight loss protocols have become the defining revenue driver for functional medicine and metabolic clinics over the past three years. Two agents dominate the landscape: semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GIP/GLP-1 receptor agonist). Both are in widespread use; both have distinct clinical profiles that should inform patient selection.
This comparison is written for clinic operators and medical directors managing active weight loss programs. It covers mechanism, clinical differentiation, protocol structure, and patient selection considerations.
Mechanism of Action
Semaglutide: GLP-1 Receptor Agonist
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone secreted in the small intestine in response to food intake. GLP-1 stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers to reduce appetite. Semaglutide has a half-life of approximately one week, enabling once-weekly subcutaneous dosing.
Tirzepatide: Dual GIP/GLP-1 Receptor Agonist
Tirzepatide acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is an incretin hormone that, in addition to its metabolic effects, appears to enhance the adipose-level response to GLP-1 signaling. The dual-receptor mechanism is associated with greater mean weight loss in trials than GLP-1 monotherapy.
Clinical trial data (SURMOUNT series) showed mean weight loss of approximately 20–22% body weight with tirzepatide 15 mg vs. approximately 15% with semaglutide 2.4 mg (STEP 1), though direct head-to-head trials with matched populations have not been published as of mid-2026.
Dosing Protocols
Semaglutide Protocol (Standard Titration)
Starting dose: 0.25 mg subcutaneous once weekly for 4 weeks. Titration: increase by 0.25 mg every 4 weeks. Target maintenance dose: 1.0–2.4 mg weekly depending on tolerance and response. The slower titration reduces GI side effects, which are the primary driver of early discontinuation.
Tirzepatide Protocol (Standard Titration)
Starting dose: 2.5 mg subcutaneous once weekly for 4 weeks. Titration: increase by 2.5 mg every 4 weeks. Target maintenance dose: 10–15 mg weekly. Titration speed can be adjusted based on GI tolerance. Some protocols hold patients at 5 mg or 7.5 mg for extended periods if tolerating poorly.
Patient Selection Considerations
When to Start with Semaglutide
Patients with significant GI sensitivity or a history of GI conditions may tolerate semaglutide's more focused mechanism better initially. Patients with a strong prior response to GLP-1 agonists (if they have previous experience). Patients for whom cost is a significant factor, as compounded semaglutide has historically been more accessible than tirzepatide.
Note: The FDA's regulatory position on compounded semaglutide and tirzepatide has been in flux throughout 2025–2026. Confirm the current status of compounding availability with your supplier before making protocol commitments to patients.
When to Consider Tirzepatide First
Patients with type 2 diabetes or significant insulin resistance, where the dual incretin mechanism offers additional metabolic benefits. Patients who tried semaglutide with insufficient response — the dual mechanism provides meaningful additional efficacy. Patients with higher baseline BMI (40+) where the greater mean weight loss data becomes clinically significant.
Side Effect Profiles
Both agents share similar GI side effect profiles: nausea, vomiting, diarrhea, and constipation are the most common adverse effects and are dose-dependent. These are most prominent during titration and typically diminish at steady state.
Tirzepatide's GI side effects are modestly higher in frequency during titration in most trials, likely due to the additive GIP mechanism. Some clinicians use a slower titration (holding at each dose for 6–8 weeks instead of 4) to improve early tolerability.
Both agents carry a class warning regarding medullary thyroid carcinoma based on rodent data; clinical relevance in humans is not established, but both agents are contraindicated in patients with personal or family history of MTC or MEN2.
Protocol Infrastructure Considerations
Monitoring
Baseline labs before starting: HbA1c, fasting glucose, lipid panel, hepatic function. Follow-up labs at 3 months minimum. Blood pressure monitoring at each visit — both agents have favorable cardiovascular profiles but patients losing significant weight rapidly can see hemodynamic changes.
Muscle Preservation
A consistent finding in GLP-1 and dual agonist weight loss trials is that a portion of weight lost is lean mass. Clinics running best-in-class programs incorporate protein optimization guidance (minimum 1.2–1.6g/kg/day), resistance training recommendations, and in some cases, concurrent protocols designed to support lean mass preservation.
Compounding Regulatory Status
The compounding landscape for both semaglutide and tirzepatide is subject to ongoing FDA review. The period of shortage-based compounding authorization that enabled widespread availability of compounded GLP-1 agents has been under pressure from name-brand manufacturers and the FDA's shortage database. Clinics should have a clear protocol for transitioning patients to FDA-approved branded agents if compounding availability is disrupted.
The Bottom Line
Both agents are highly effective. Tirzepatide shows greater mean weight loss in available trial data. Semaglutide has a longer clinical track record in widespread practice. Patient selection, GI tolerance, and cost access should guide the choice for most patients, with tirzepatide as the preferred first-line choice for patients with insulin resistance or who need maximum efficacy.